The price of Clover Health Investments Corp (NASDAQ:CLOV) shares last traded on Wall Street rose 5.54% to $3.05.
CLOV stock price is now -3.29% away from the 50-day moving average and -14.51% away from the 200-day moving average. The market capitalization of the company currently stands at $1.55B.
With the price target of $6, Craig Hallum recently initiated with Buy rating for Clover Health Investments Corp (NASDAQ: CLOV). On October 07, 2024, UBS recently initiated its ‘Neutral’ rating on the stock quoting a target price of $4, while ‘Cowen’ rates the stock as ‘Market Perform’
In other news, Reynoso Jamie L., CEO, Medicare Advantage sold 19,789 shares of the company’s stock on Jul 03 ’25. The stock was sold for $51,056 at an average price of $2.58. Upon completion of the transaction, the CEO, Medicare Advantage now directly owns 3,308,539 shares in the company, valued at $10.09 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 07 ’25, CEO, Medicare Advantage Reynoso Jamie L. sold 2,012 shares of the business’s stock. A total of $5,734 was realized by selling the stock at an average price of $2.85. This leaves the insider owning 3,297,821 shares of the company worth $10.06 million. A total of 24.85% of the company’s stock is owned by insiders.
During the past 12 months, Clover Health Investments Corp has had a low of $1.27 and a high of $4.87. The fifty day moving average price for CLOV is $3.1536 and a two-hundred day moving average price translates $3.5676 for the stock.
The latest earnings results from Clover Health Investments Corp (NASDAQ: CLOV) was released for 2025-03-31. The net profit margin was -1.69% and return on equity was -7.75% for CLOV. The company reported revenue of $462.33 million for the quarter, compared to $346.92 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 33.27 percent. For the current quarter, analysts expect CLOV to generate $468.3M in revenue.
